Foresite Capital Management VI LLC
Annual return '25
+9.1%
SPY '25
+17.7%
Alpha
-8.7ptsvs SPY
Invested
$460.3M
Holdings
17
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 97%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$CGON
CG Oncology, Inc.
Q4 2025: Exited (was 2.22M shares)
32.7%
02
$ALMS
ALUMIS INC.
Q4 2025: Exited (was 4.25M shares)
20.3%
03
$CNTA
Centessa Pharmaceuticals plc
Q4 2025: Exited (was 1.31M shares)
11.8%
04
$CRVS
Corvus Pharmaceuticals, Inc.
Q4 2025: Exited (was 1.73M shares)
5.8%
05
$DNLI
Denali Therapeutics Inc.
Q4 2025: Exited (was 1.00M shares)
5.0%
06
$AGIO
AGIOS PHARMACEUTICALS, INC.
Held since at least Q1 2024
3.9%
07
$VSTM
Verastem, Inc.
Q4 2025: Exited (was 2.62M shares)
3.6%
08
$KYMR
Kymera Therapeutics, Inc.
Q4 2025: Exited (was 146.3k shares)
2.6%
09
$NERV
Minerva Neurosciences, Inc.
Held since at least Q1 2024
2.6%
10
$CLDX
Celldex Therapeutics, Inc.
Held since at least Q1 2024
2.2%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 10:32 UTC.